Skip to main content
profile image
Selected Works of Carlo B. Bifulco, M.D.
Article
Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.
Journal of Clinical Oncology (2016)
  • Jerome Galon, French Institute of Health and Medical Research
  • Bernhard Mlecnik, French Institute of Health and Medical Research
  • Florence Marliot, French Institute of Health and Medical Research
  • Fang-Shu Ou, Mayo Clinic
  • Carlo Bruno Bifulco, Providence Portland Medical Center
  • Alessandro Lugli, University of Bern
  • Inti Zlobec, University of Bern
  • Tilman T. Rau, Institute of Pathology, University Medical Center Erlangen, Erlangen, Germany;
  • Arndt Hartmann, University of Erlangen-Nuremberg
  • Giuseppe V. Masucci, Karolinska Institutet
  • Eva Zavadova, First Faculty of Medicine, Charles University in Prague
  • Pam Ohashi, Princess Margaret Cancer Centre
  • Michael H. A. Roehrl, University Health Network
  • Yutaka Kawakami, Division of Cellular Signaling, Institute for Advanced Medical Research, Tokyo, Japan;
  • Toshihiko Torigoe, Sapporo Medical University
  • Paolo Antonio Ascierto, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy;
  • Franco Marincola, Qatar Airways
  • Daniel J. Sargent, Mayo Clinic
  • Bernard A. Fox, Providence Portland Medical Center
  • Franck Pages, French Institute of Health and Medical Research
Link
Disciplines
Publication Date
May 20, 2016
DOI
10.1200/JCO.2016.34.15_SUPPL.3500
Citation Information
Jerome Galon, Bernhard Mlecnik, Florence Marliot, Fang-Shu Ou, et al.. "Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients." Journal of Clinical Oncology Vol. 34 (2016) p. 3500 - 3500
Available at: http://works.bepress.com/carlo-bifulco/88/